BR112014004306A2 - fotossensibilizadores de (bacterio)clorofila para tratamento de doenças e distúrbios do olho - Google Patents

fotossensibilizadores de (bacterio)clorofila para tratamento de doenças e distúrbios do olho

Info

Publication number
BR112014004306A2
BR112014004306A2 BR112014004306A BR112014004306A BR112014004306A2 BR 112014004306 A2 BR112014004306 A2 BR 112014004306A2 BR 112014004306 A BR112014004306 A BR 112014004306A BR 112014004306 A BR112014004306 A BR 112014004306A BR 112014004306 A2 BR112014004306 A2 BR 112014004306A2
Authority
BR
Brazil
Prior art keywords
bacterio
photosensitizers
chlorophyll
disorders
eye diseases
Prior art date
Application number
BR112014004306A
Other languages
English (en)
Portuguese (pt)
Inventor
Avigdor Scherz
Yoram Salomon
Arie Marcovich
Alexander Brandis
Daniel Wagner
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of BR112014004306A2 publication Critical patent/BR112014004306A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014004306A 2011-08-23 2012-08-23 fotossensibilizadores de (bacterio)clorofila para tratamento de doenças e distúrbios do olho BR112014004306A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526414P 2011-08-23 2011-08-23
PCT/IL2012/050325 WO2013027222A1 (en) 2011-08-23 2012-08-23 (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders

Publications (1)

Publication Number Publication Date
BR112014004306A2 true BR112014004306A2 (pt) 2017-03-28

Family

ID=46889394

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004306A BR112014004306A2 (pt) 2011-08-23 2012-08-23 fotossensibilizadores de (bacterio)clorofila para tratamento de doenças e distúrbios do olho

Country Status (20)

Country Link
US (4) US9452172B2 (cg-RX-API-DMAC7.html)
EP (1) EP2747763B1 (cg-RX-API-DMAC7.html)
JP (1) JP6215203B2 (cg-RX-API-DMAC7.html)
KR (1) KR101962991B1 (cg-RX-API-DMAC7.html)
CN (1) CN103930108B (cg-RX-API-DMAC7.html)
AU (1) AU2012298156B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014004306A2 (cg-RX-API-DMAC7.html)
CA (1) CA2846011C (cg-RX-API-DMAC7.html)
CL (1) CL2014000432A1 (cg-RX-API-DMAC7.html)
DK (1) DK2747763T3 (cg-RX-API-DMAC7.html)
ES (1) ES2856698T3 (cg-RX-API-DMAC7.html)
HK (1) HK1199412A1 (cg-RX-API-DMAC7.html)
HU (1) HUE053321T2 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN02153A (cg-RX-API-DMAC7.html)
MX (1) MX360683B (cg-RX-API-DMAC7.html)
PE (1) PE20141183A1 (cg-RX-API-DMAC7.html)
PT (1) PT2747763T (cg-RX-API-DMAC7.html)
RU (1) RU2632439C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013027222A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201402056B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP3494974B1 (en) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
EP4420725A3 (en) 2012-03-29 2025-04-16 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
WO2017015471A1 (en) 2015-07-21 2017-01-26 Avedro, Inc. Systems and methods for treaments of an eye with a photosensitizer
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
CN105601638B (zh) * 2016-01-28 2018-10-26 东北林业大学 一种叶绿酸衍生物及其制备方法、作为光敏抑菌剂及光敏杀虫剂的应用
US10342697B2 (en) 2016-04-13 2019-07-09 Avedro, Inc. Systems and methods for delivering drugs to an eye
EP4335419A3 (en) * 2016-05-05 2024-04-03 David Muller Corneal implant systems and methods
US10849855B2 (en) * 2017-01-03 2020-12-01 Vitrean, Inc. Methods and devices for treating a retinal detachment
WO2019028250A1 (en) 2017-08-02 2019-02-07 The University Of Chicago NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF
CN109091685A (zh) * 2018-08-10 2018-12-28 北京市眼科研究所 一种对角膜炎提取细菌病原体的灭活方法
KR20210093901A (ko) * 2018-10-24 2021-07-28 캘리포니아 인스티튜트 오브 테크놀로지 일중항 산소를 사용한 근시 및 기타 안구 질환의 치료
US11702546B2 (en) 2018-10-24 2023-07-18 California Institute Of Technology Near-infrared heptamethine dyes for generation of singlet oxygen
WO2020117974A1 (en) * 2018-12-04 2020-06-11 Avedro, Inc. Compounds and compositions for eye treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102645A (en) 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
RU2201219C2 (ru) * 2001-04-24 2003-03-27 Макаров Константин Алексеевич Фармакологическая композиция пролонгированного действия
US20040266748A1 (en) * 2001-10-03 2004-12-30 Robinson Byron C Photosensitizing carbamate derivatives
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
EP1753457B8 (en) * 2004-06-07 2016-09-21 Yeda Research And Development Co., Ltd. Cationic bacteriochlorophyll derivatives and uses thereof
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
KR101502632B1 (ko) 2006-10-24 2015-03-17 캘리포니아 인스티튜트 오브 테크놀로지 신체 조직의 물리적 및/또는 화학적 성질에 영향을 주는 광화학적 요법
RU2404768C1 (ru) * 2009-10-28 2010-11-27 Федеральное агентство по науке и инновациям Глазные капли
JPWO2011099602A1 (ja) * 2010-02-12 2013-06-17 学校法人日本大学 ポルフィリン誘導体および放射線力学療法におけるその使用

Also Published As

Publication number Publication date
DK2747763T3 (da) 2021-03-29
ZA201402056B (en) 2015-11-25
JP6215203B2 (ja) 2017-10-18
US20190231874A1 (en) 2019-08-01
US20140378888A1 (en) 2014-12-25
CN103930108B (zh) 2017-05-24
CL2014000432A1 (es) 2014-11-28
RU2632439C2 (ru) 2017-10-04
MX2014002107A (es) 2015-04-16
US20160354468A1 (en) 2016-12-08
AU2012298156A1 (en) 2014-04-10
EP2747763B1 (en) 2020-12-30
HUE053321T2 (hu) 2021-06-28
PT2747763T (pt) 2021-02-22
IN2014CN02153A (cg-RX-API-DMAC7.html) 2015-05-29
KR20140088514A (ko) 2014-07-10
CN103930108A (zh) 2014-07-16
US9452172B2 (en) 2016-09-27
ES2856698T3 (es) 2021-09-28
MX360683B (es) 2018-11-13
HK1199412A1 (en) 2015-07-03
JP2014524465A (ja) 2014-09-22
WO2013027222A1 (en) 2013-02-28
US11058772B2 (en) 2021-07-13
KR101962991B1 (ko) 2019-03-27
EP2747763A1 (en) 2014-07-02
CA2846011A1 (en) 2013-02-28
CA2846011C (en) 2019-10-15
US20210330792A1 (en) 2021-10-28
AU2012298156B2 (en) 2017-08-17
PE20141183A1 (es) 2014-10-05
RU2014110784A (ru) 2015-09-27

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
PT2877184T (pt) Composições e tratamento para doenças e distúrbios oculares
ZA201402056B (en) (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders
BR112013007678A2 (pt) método para tratamento de doenças alérgicas
BR112013018469A2 (pt) dispositivos e métodos para tratamento de tecidos
IL260714B (en) Methods for the treatment and diagnosis of blinding eye diseases
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
IL238432A0 (en) Methods and devices for the treatment of ocular diseases in human subjects
IL229257A0 (en) Compositions and methods for treating retinal diseases
PL3251666T3 (pl) Sposób leczenia urazu neurologicznego
HUE037660T2 (hu) Androgén készítmény szembetegség kezelésére
PT2909317T (pt) Métodos e composições para tratamento e controlo de doenças de plantas
BR112013024169A2 (pt) método para o tratamento e prevenção da doença de parkinson
BR112013030381A2 (pt) reagentes e métodos para tratar doença dental
DK2701697T3 (da) Oxidative nethindesygdomme
IL232710B (en) L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
BR112014004414A2 (pt) composições e métodos para tratar doença neurodegenerativa
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
BR112014016108A2 (pt) método de tratamento de perda óssea alvelar
SG11201503231YA (en) METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES
LTPA2020511I1 (lt) Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
PT2718434T (pt) Composições e métodos para tratar a doença de espru celíaco
BR112013023142A2 (pt) método de tratamento de cabelos
BR112013030370A2 (pt) compostos de quinona para tratamento de doenças mediadas por ape1
BR112014029487A2 (pt) método para o tratamento cosmético

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2634 DE 29-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.